AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02147756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2RE
Description: Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation.
Study NCT02147756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repair
Study NCT03395431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fingerprick autologuos blood (FAB)
Description: Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
Study NCT03973242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual focus with narrow band imaging
Description: dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
Study NCT03973242 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dual focus with narrow band imaging
Description: dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
Study NCT03879889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
Study NCT04514601 — intervention group
Intervention type: OTHER
Intervention: Standard Operating Protocol
Description: This was a written protocol on how the handover process should be conducted.
Study NCT03689764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive video game-based exercise
Description: Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
Study NCT03689764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
Study NCT03811652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
Study NCT04339816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: orally or into nasogastric tube for 5 days
Study NCT04339816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: orally or into nasogastric tube for 5 days
Study NCT04339816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: orally or into nasogastric tube for 5 days
Study NCT04310761 — intervention group
Intervention type: PROCEDURE
Intervention: one single blastocyst transfer, both fresh and warmed
Description: Ultrasound guided transvaginal embryo transfer.
Study NCT04339816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally or into nasogastric tube for 5 days
Study NCT04339816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: orally or into nasogastric tube for 5 days
Study NCT01242592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tuberculosis Treatment
Study NCT01242592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Tuberculosis Treatment
Study NCT00179413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG -Intron
Study NCT00179413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.6mg twice a day
Study NCT03764644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined ABMT and CBT
Description: ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
Study NCT03764644 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Combined Sham ABMT and CBT
Description: ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
Study NCT02609061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Open flap debridement (OFD) alone
Study NCT02609061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
Study NCT02609061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
Study NCT03309683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Quick Clip Pro - Single Use Repositionable Clips
Description: A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
Study NCT01701661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: stripping of main trunk or if previously removed, removal or ligating the refluating trunk
Study NCT01701661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: Compression stockings class II
Study NCT02171598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT02171598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran high dose
Study NCT02171598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran low dose
Study NCT00694967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: McDonald cerclage placement
Description: Transcervical McDonald cerclage placement
Study NCT03448380 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Libre Flash Glucose Monitoring System
Description: Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
Study NCT05307926 — intervention group
Intervention type: DRUG
Intervention: PD-1 inhibitors
Description: For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
Study NCT00694967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 hydroxyprogesterone caproate
Description: Weekly 250mg intramuscular injections
Study NCT03437200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
Study NCT03437200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
Study NCT03437200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
Study NCT03331068 — intervention group
Intervention type: BEHAVIORAL
Intervention: online questionnaire of MAX-PC
Description: Scale measuring of the anxiety specific of prostate cancer, French version.
Study NCT02008500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash
Description: 15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
Study NCT02008500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Mouthwash
Description: 15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
Study NCT02008500 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non Herbal Mouthwash
Description: 15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
Study NCT01479803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture with fine needle aspiration under endoscopic ultrasonographic control
Description: Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
Study NCT01418209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose 17-ß-estradiol with progesterone taper
Description: Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
Study NCT01418209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
Study NCT01418209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive pill that looks like the active medication.
Study NCT00101101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study NCT00101101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study NCT00101101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study NCT00101101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study NCT00101101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Study NCT00101101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Cell-Based Vaccine
Description: Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
Study NCT00101101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
Study NCT01180738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body weight supported treadmill training
Description: Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
Study NCT01180738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Overground walking training
Description: Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
Study NCT02419846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
Study NCT02419846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital rectal examination
Description: Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
Study NCT02419846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-test administration
Description: 15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
Study NCT02419846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Survey will be administered at the end of the program for participants to assess their experience
Study NCT02419846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen measurement
Description: PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
Study NCT02419846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post test administration
Description: Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
Study NCT03494036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: capsule
Study NCT03494036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study NCT05307926 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
Study NCT00258310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine 1000mg/day for one year
Study NCT00258310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery, chemotherapy and/or radiotherapy
Description: Surgery, chemotherapy and/or radiotherapy
Study NCT00462241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chiropractic treatment
Description: Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
Study NCT00462241 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-management
Description: Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
Study NCT00474370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: One tablet of vicriviroc 30 mg once daily.
Study NCT00474370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo once daily.
Study NCT00495716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
Study NCT00495716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: 400 mg acyclovir orally twice daily for 1 year
Study NCT04519658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily
Study NCT04519658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets by mouth once daily
Study NCT02976896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.